Fungal endocarditis

Ricardo M. La Hoz, John W. Baddley

Research output: Contribution to journalReview article

Abstract

Fungal endocarditis (FE) is an uncommon infection that is associated with substantial morbidity and mortality. The incidence of FE is expected to rise in the future owing to an increase in the populations at risk, as well as increasing use of prosthetic heart materials and implantable electronic devices. The most common causative organisms are Candida and Aspergillus spp.; however, multiple fungal spp. have been implicated. A high degree of clinical suspicion is crucial for the diagnosis of FE, given that blood cultures have low sensitivity for diagnosis. For this reason, it is imperative that histopathological examinations are performed and cultures of intraoperative valve and tissue specimens are obtained. Current practice guidelines recommend valve replacement for FE, if feasible, combined with prolonged antifungal therapy for the treatment of both native and prosthetic valve FE. A liposomal formulation of amphotericin B with or without flucytosine is recommended as the treatment of choice for patients with Candida endocarditis. For Aspergillus endocarditis, the treatment of choice is voriconazole. This review will focus on the current epidemiology, treatment, and outcomes of FE complicating valves and electronic implantable or circulatory support devices.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalJournal of Invasive Fungal Infections
Volume5
Issue number2
StatePublished - Dec 16 2011

Fingerprint

Endocarditis
Aspergillus
Candida
Flucytosine
Equipment and Supplies
Therapeutics
Practice Guidelines
Epidemiology
Morbidity
Mortality
Incidence
Infection

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases
  • Immunology and Allergy

Cite this

Fungal endocarditis. / La Hoz, Ricardo M.; Baddley, John W.

In: Journal of Invasive Fungal Infections, Vol. 5, No. 2, 16.12.2011, p. 31-36.

Research output: Contribution to journalReview article

La Hoz, RM & Baddley, JW 2011, 'Fungal endocarditis', Journal of Invasive Fungal Infections, vol. 5, no. 2, pp. 31-36.
La Hoz, Ricardo M. ; Baddley, John W. / Fungal endocarditis. In: Journal of Invasive Fungal Infections. 2011 ; Vol. 5, No. 2. pp. 31-36.
@article{ccddc4ebd37b4f5ab5eef91992c7405b,
title = "Fungal endocarditis",
abstract = "Fungal endocarditis (FE) is an uncommon infection that is associated with substantial morbidity and mortality. The incidence of FE is expected to rise in the future owing to an increase in the populations at risk, as well as increasing use of prosthetic heart materials and implantable electronic devices. The most common causative organisms are Candida and Aspergillus spp.; however, multiple fungal spp. have been implicated. A high degree of clinical suspicion is crucial for the diagnosis of FE, given that blood cultures have low sensitivity for diagnosis. For this reason, it is imperative that histopathological examinations are performed and cultures of intraoperative valve and tissue specimens are obtained. Current practice guidelines recommend valve replacement for FE, if feasible, combined with prolonged antifungal therapy for the treatment of both native and prosthetic valve FE. A liposomal formulation of amphotericin B with or without flucytosine is recommended as the treatment of choice for patients with Candida endocarditis. For Aspergillus endocarditis, the treatment of choice is voriconazole. This review will focus on the current epidemiology, treatment, and outcomes of FE complicating valves and electronic implantable or circulatory support devices.",
author = "{La Hoz}, {Ricardo M.} and Baddley, {John W.}",
year = "2011",
month = "12",
day = "16",
language = "English (US)",
volume = "5",
pages = "31--36",
journal = "Journal of Invasive Fungal Infections",
issn = "1753-3783",
publisher = "Remedica Medical Education and Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Fungal endocarditis

AU - La Hoz, Ricardo M.

AU - Baddley, John W.

PY - 2011/12/16

Y1 - 2011/12/16

N2 - Fungal endocarditis (FE) is an uncommon infection that is associated with substantial morbidity and mortality. The incidence of FE is expected to rise in the future owing to an increase in the populations at risk, as well as increasing use of prosthetic heart materials and implantable electronic devices. The most common causative organisms are Candida and Aspergillus spp.; however, multiple fungal spp. have been implicated. A high degree of clinical suspicion is crucial for the diagnosis of FE, given that blood cultures have low sensitivity for diagnosis. For this reason, it is imperative that histopathological examinations are performed and cultures of intraoperative valve and tissue specimens are obtained. Current practice guidelines recommend valve replacement for FE, if feasible, combined with prolonged antifungal therapy for the treatment of both native and prosthetic valve FE. A liposomal formulation of amphotericin B with or without flucytosine is recommended as the treatment of choice for patients with Candida endocarditis. For Aspergillus endocarditis, the treatment of choice is voriconazole. This review will focus on the current epidemiology, treatment, and outcomes of FE complicating valves and electronic implantable or circulatory support devices.

AB - Fungal endocarditis (FE) is an uncommon infection that is associated with substantial morbidity and mortality. The incidence of FE is expected to rise in the future owing to an increase in the populations at risk, as well as increasing use of prosthetic heart materials and implantable electronic devices. The most common causative organisms are Candida and Aspergillus spp.; however, multiple fungal spp. have been implicated. A high degree of clinical suspicion is crucial for the diagnosis of FE, given that blood cultures have low sensitivity for diagnosis. For this reason, it is imperative that histopathological examinations are performed and cultures of intraoperative valve and tissue specimens are obtained. Current practice guidelines recommend valve replacement for FE, if feasible, combined with prolonged antifungal therapy for the treatment of both native and prosthetic valve FE. A liposomal formulation of amphotericin B with or without flucytosine is recommended as the treatment of choice for patients with Candida endocarditis. For Aspergillus endocarditis, the treatment of choice is voriconazole. This review will focus on the current epidemiology, treatment, and outcomes of FE complicating valves and electronic implantable or circulatory support devices.

UR - http://www.scopus.com/inward/record.url?scp=83355165024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83355165024&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 31

EP - 36

JO - Journal of Invasive Fungal Infections

JF - Journal of Invasive Fungal Infections

SN - 1753-3783

IS - 2

ER -